The Uromigos
Advertisement
Tom and Brian are joined by David Penson to discuss upcoming presentations to look forward to at AUA.
Dr. Silke Gillessen gives a summary of APCCC 2024, including surgery versus RT, genetic and somatic testing, and more.
Chris Sweeney is joined by fellow experts to discuss mHSPC side effects such as bone weakness, hot flashes, and gynecomastia.
Professor Thomas Suter and Dr. Chuck Ryan discuss cardiovascular risks associated with hormone therapy in prostate cancer.
Drs. Thomas Zilli and Pierre Blanchard debate the use of radiation therapy in prostate cancer and oligometastatic disease.
Brian and Tom speak with Drs. Piet Ost and Jason Efstathiou on the data for and against radiation therapy in prostate cancer.
Alison Birtle gives an update on the POUT trial on the use of adjuvant chemotherapy after nephroureterectomy for UTUC.
Daniel Goldstein returns to the podcast to discuss dosing changes in drugs such as nivolumab and pembrolizumab.
Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer.
Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.
Michiel Van der Heijdan explores the role of radiotherapy and other neoadjuvant combinations for MIBC.
Dr. Galsky discusses his phase 2 study evaluating the effects of gem/cis/nivo followed by nivolumab in responders.
FDA Deputy Oncology Director Dan Suzman describes approaches to oncology trials in the GU setting.
Dr. Tanya Dorff discusses her work on a phase 1 study investigating acapatamab for advanced prostate cancer.
Michael Lattanzi, MD, joins the podcast to discuss treatment plans and research in the community oncology setting.
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer.
Reviewing the top presentations from ASCO GU 2024, including the phase III GETUG-AFU-18 study, CONTACT-02, and more.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.